CameronJohnTurtleMD
Hematology • Seattle, WAInstructor, Medicine, University of Washington School of Medicine
Are you Dr. Turtle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-228-1025
Summary
- Dr. Cameron Turtle, MD is a hematologist in Seattle, Washington. He is currently licensed to practice medicine in Washington. He is affiliated with Fred Hutch Cancer Center and UW Medicine/University of Washington Medical Center.
Education & Training
University of Sydney Faculty of MedicineClass of 1993
Certifications & Licensure
WA State Medical License 2007 - 2022
Clinical Trials
- JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Nov 15
- huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Start of enrollment: 2017 Nov 03
Publications & Presentations
PubMed
- 471 citationsDurable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of IbrutinibCameron J. Turtle, Kevin A. Hay, Laila-Aicha Hanafi, Daniel Li, Sindhu Cherian
Journal of Clinical Oncology. 2017-07-17 - 755 citationsImmunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cellsCameron J. Turtle, Laila-Aicha Hanafi, Carolina Berger, Michael Hudecek, Barbara S. Pender
Science Translational Medicine. 2016-09-07 - 1457 citationsCD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsCameron J. Turtle, Laïla Aïcha Hanafi, Carolina Berger, Ted Gooley, Sindhu Cherian
The Journal of Clinical Investigation. 2016-06-01
Press Mentions
Patient and Family Experience with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN) Amyloidosis: Results of Two Focus GroupsFebruary 8th, 2021- Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. To Its Scientific Advisory BoardNovember 9th, 2020
Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019- Join now to see all
